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Abstract
Background: Given the vast range of molecular mechanisms giving rise to breast cancer, it is unlikely universal
cures exist. However, by providing a more precise prognosis for breast cancer patients through integrative models,
treatments can become more individualized, resulting in more successful outcomes. Specifically, we combine gene
expression, pseudogene expression, miRNA expression, clinical factors, and pseudogene-gene functional networks
to generate these models for breast cancer prognostics. Establishing a LASSO-generated molecular gene signature
revealed that the increased expression of genes STXBP5, GALP and LOC387646 indicate a poor prognosis for a
breast cancer patient. We also found that increased CTSLP8 and RPS10P20 and decreased HLA-K pseudogene
expression indicate poor prognosis for a patient. Perhaps most importantly we identified a pseudogene-gene
interaction, GPS2-GPS2P1 (improved prognosis) that is prognostic where neither the gene nor pseudogene alone is
prognostic of survival. Besides, miR-3923 was predicted to target GPS2 using miRanda, PicTar, and TargetScan,
which imply modules of gene-pseudogene-miRNAs that are potentially functionally related to patient survival.
Results: In our LASSO-based model, we take into account features including pseudogenes, genes and candidate
pseudogene-gene interactions. Key biomarkers were identified from the features. The identification of key
biomarkers in combination with significant clinical factors (such as stage and radiation therapy status) should be
considered as well, enabling a specific prognostic prediction and future treatment plan for an individual patient.
Here we used our PseudoFuN web application to identify the candidate pseudogene-gene interactions as
candidate features in our integrative models. We further identified potential miRNAs targeting those features in our
models using PseudoFuN as well. From this study, we present an interpretable survival model based on LASSO and
decision trees, we also provide a novel feature set which includes pseudogene-gene interaction terms that have
been ignored by previous prognostic models. We find that some interaction terms for pseudogenes and genes are
significantly prognostic of survival. These interactions are cross-over interactions, where the impact of the gene
expression on survival changes with pseudogene expression and vice versa. These may imply more complicated
regulation mechanisms than previously understood.
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Conclusions: We recommend these novel feature sets be considered when training other types of prognostic
models as well, which may provide more comprehensive insights into personalized treatment decisions.
Keywords: Data integration, Breast cancer, Survival prognosis, Pseudogenes, Non-coding RNAs, RNA-Seq, Network
analysis, Cox regression, Database
Introduction
Breast cancer is the second most common cancer among
women [1] and the second-leading cause of cancer death
[2], indicating a widespread, detrimental effect on the
population as a whole. The high death-rate is due to the
complexity of the disease -- each case is unique, with
different clinical and molecular characteristics which
makes a single “silver bullet” treatment unlikely [3].
These considerations make personalized treatments a
more promising route. Indeed, we see that individuals
with the HER2-positive breast cancer subtype are treated
with drugs designed to specifically target the surface
HER2/neu proteins, such as Trastuzumab [4]. ER/PR-
positive patients are treated with hormone therapy, as
they are hormone sensitive and tend to have better out-
comes. In contrast, patients with triple-negative breast
cancer (TNBC) would not respond to such hormonal
treatments as their cancer is not proliferated by hor-
mones and tends to be more aggressive [5]. Current
TNBC treatments include p53 (e.g., using drug taxanes)
and cell proliferation targeted therapies, given the higher
response rates using chemotherapy than in other types
of breast cancer [5]. These past successes show personal-
ized treatment plans with a greater degree of efficacy
must account for a comprehensive understanding of that
specific tumor and tumor microenvironment.
Cancerous states arise from mutations and tissue dys-
regulation, and these alterations are usually associated
with abnormal gene expressions. For example, in aggres-
sive B-cell lymphoma tumors resulting from an alter-
ation in the p53 tumor suppressor, an overexpression of
p14ARF was observed, suggesting its potential as a cell
cycle regulator and a marker of high tumor severity [6].
Differential expression of specific genes have been found
to lead to tumor development, such as ITGA11 and
JAB1, which have been discovered to be biomarkers in
breast cancer [7]. High levels of STAT1 have been
detected in a subset of breast cancers, resulting in the
induction of known IFN-regulated genes [8]. It is there-
fore possible to infer the underlying mechanism of spe-
cific cancer types through the measurement of mRNA
expression in RNA-Seq and microarrays, leading to per-
sonalized medicine assays such as OncotypeDx [9, 10].
Expression of miRNAs, a class of short non-coding
RNA sequences, can also play a role in tumorigenesis by
mediating gene expression [11]. These sequences are
also very common, with over 2500 sequences annotated
in the human genome [7]. Already multiple associations
with diseases and targetability by antisense inhibition
make them a promising therapeutic target [12]. It has
been discovered that about half of the known human
miRNAs are related to cancer, influencing gene expres-
sion levels, which in turn impacts all aspects of the dis-
ease, from progression to remission [13]. Given that
miRNA dysregulation impacts their regulatory function
over cell proliferation, adhesion, and migration processes
[2], these sequences thus have the potential to be signifi-
cant biomarkers in breast cancer. This idea has been ex-
plored in previous studies, with findings indicating that
miR-320a, miR-361-5p, and miR-21-5p may lead to a
higher survival rate in breast cancer [2]. A correlation
has been discovered between poor survival rates and de-
creased miR-200b expression levels, with an upregula-
tion in miR-200 leading to improved colonization and
proliferation suppression in cancer cell lines [14]. Ex-
pression levels of miRNAs should therefore be consid-
ered when predicting prognosis and establishing a
treatment plan. Gene regulatory relationships are not
limited to gene-miRNA interactions and in fact pseudo-
gene regulation has been observed as well [15].
Pseudogenes have been shown to affect the regula-
tory mechanisms in pan-cancer studies [16]. Further-
more, pseudogene expression can be used as a novel
marker to stratify patient subtypes in multiple cancer
types [17] which implies these regulatory relationships
should be taken into account in cancer survival prog-
nosis. More specifically, individual pseudogenes have
been implicated and externally validated as regulators
of their parent genes [15]. One such example PTEN
(gene)-PTENP1 (pseudogene) interaction has been
implicated in prostate cancer due to the competing
endogenous RNA (ceRNA) network they participate
in18. There are a multitude of other regulatory
pseudogene-gene relationships that have been vali-
dated including FTH1-FTH1PX (X denotes multiple
pseudogenes) in prostate cancer [18], SUMO1-
SUMO1P3 in gastric cancer [19], ATP8A2-ATP8A2Ψ
in breast cancer [16]. These examples provide compel-
ling evidence that pseudogene-gene interactions can
be directly used as prognostic features in human can-
cer but to fully utilize these relationships it is import-
ant to identify candidate interactions.
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Candidate interactions can be uncovered using direct
1:1 pseudogene to gene parent mappings; however, these
interactions do not take into account the wider array of
sequence homology relationships that may cause regula-
tion. For this purpose, we use the idea of pseudogene-
gene networks, which are networks of pseudogenes and
genes that have high sequence homology and as a result
may be functionally related [20]. These functional rela-
tionships are taken from the Pseudogene Functional
Network (PseudoFuN) database [21] so that pseudo-
genes and genes could be mapped back to prospective
regulatory partners.
Given the recent technological rise in next- and third-
generation sequencing, the establishment of large
genomic databases and effective computational and stat-
istical methods enabled the potential to uncover new
findings on cancer biology through bioinformatic ana-
lysis. One database, The Cancer Genome Atlas (TCGA)
[22], contains genomic and clinical data on thousands of
individuals that suffered from an array of cancer types.
Utilizing their breast invasive carcinoma (BRCA) data-
sets, we can determine the prognosis of an individual
based on clinical, molecular features, and molecular in-
teractions and generate efficient, interpretable diagrams
as a novel prognostic tool as well as to guide for treat-
ment decisions.
Distilling the large numbers of candidate features
down to usable subsets is a common problem in
biomedical data analytics [23] which was first manifested
as the “curse of dimensionality” as early as 1957 [24].
Univariate feature selection is an approach addressing
the “curse of dimensionality” common in biomedical sci-
ences because it allows the features to be ranked on
their individual ability to predict the dependent variable
[25, 26]. More specifically these methods have been ap-
plied directly with univariate Cox proportional hazards
models [27]. Univariate feature selection has a long his-
tory of use [28] due to its computational efficiency and
ability to rank genes based on their individual predictive
power [25]. For these reasons, we first apply the univari-
ate Cox proportional hazards models to filter down the
pool of candidate features, followed by multivariate
LASSO-Cox models for feature selection.
In order to efficiently interpret an individual’s progno-
sis, decision tree models will be generated based on the
features selected by the above multivariate models con-
sidering both molecular and clinical factors, as this ap-
proach has been known to have high prediction
accuracy [29]. This specific form of modeling is capable
of handling common difficulties in bioinformatic data-
sets, such as their high dimensional data from large sam-
ple sizes. This model’s popularity also stems from its
straightforward interpretation. The implemented algo-
rithm follows a feature selection procedure, sorting out
the most significant factors that influence the outcome,
which in this case is a patient’s overall survival (OS). In
a decision tree, the particular feature, or factor, then
splits the samples into daughter nodes, followed by re-
cursive repetition of the whole process into further
nodes until the desired stopping criterion is reached [29,
30]. Ultimately, the most influential factors across all
molecular and clinical data will be integrated as nodes in
an interpretable tree, leading to the most probable sur-
vival curve for a specific individual given the values of
molecular and clinical features. This enables the medical
team to construct an appropriate treatment plan given
the patient’s precise prognosis.
Materials and methods
Clinical and molecular data acquisition and alignment
We acquired the clinical data associated with BRCA
samples, including the patients’ days to death, days to
last follow up, vital status, pathological stage, histological
type, number of lymph nodes, gender and race from
Broad GDAC Firehose portal [22]. The pseudogene ex-
pression was downloaded from dreamBase [31]. The
data was filtered to include only patient IDs present in
the RNA expression datasets (mRNA, miRNA, and
pseudogene expression). We compiled the overall sur-
vival time by assessing the vital status, utilizing the days
to death value if the patient is deceased, or the days to
last follow up value if the patient is alive. A Kaplan-
Meier plot was used to visualize the overall survival data,
comparing the proportion of patients that were still alive
versus the survival time. To compare the survival data
with RNA expression, the clinical and expression data
were formatted, maintaining only matching patients
samples and removing any NAs that were present. The
normalized expression data (e.g., RPKM) was converted
by a log2 transformation. The final processed gene
mRNA and clinical datasets contained 765 patient sam-
ples and 20,532 genes. The processed pseudogene RNA
and clinical datasets contained 1077 patient samples and
7146 pseudogenes. There were 762 patients that were
contained in both the gene and pseudogene expression
matrices. The general workflow of our analysis is sum-
marized in Fig. 1.
Screening for significantly expressed genes and
pseudogenes
The screening was performed on the gene expression
matrix and the pseudogene expression matrix inde-
pendently using univariate Cox model for each gene
or pseudogene, so that the pool of candidate features
was selected in each dataset separately. A feature in-
dicates one gene or pseudogene in the full gene set
(G) or pseudogene set (P) depending on the expres-
sion matrix that is being used in this section. With
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the intention of deriving a molecular signature of
genes that indicate a patient’s prognosis based on
their expression values, we first split two-thirds of the
data into a training set (67%) and the remainder into
a test set (33%), then constructed a univariate Cox
model to test the significance of each feature (gene/
pseudogene). For each feature, a univariate Cox model
was fit on the training set and the p-value of score
test calculated on the same training set. (The test set
will be used in testing LASSO-Cox regression
models.) These p-values were corrected using
Benjamini-Hochberg procedure (BH-FDR). All fea-
tures with a BH-FDR below 0.05 were used as our
top features (i.e., pool of candidate features) in the
following analysis. Specifically, for each gene or
pseudogene (j ∈ {G, P}) across all patients (i), the fol-
lowing model was fit:
h tjXi; j
  ¼ h0 tð Þ exp Xi; jβ j
 
;
where t is the time point, X is the expression matrix,
and β are the coefficients of the model. h0(t) is the base-
line hazard function, and h(t| Xi, j) is the hazard function
for individual i at time t using the j th expression profile.
The hazard ratio was calculated using Cox regression
and log-rank test was performed to see if the hazard ra-
tio was significantly different than 1. The preselected
gene set (g) and pseudogene set (p) were used for further
analysis.
LASSO-Cox regression on top features from screening
In order to enhance prediction accuracy, we utilized a
multivariate LASSO-Cox model [32] on our training set,
and test its predictive performance on the test set.
Fig. 1 General workflow identifying genes, pseudogenes, and gene-pseudogene functional relationships that are prognostic of breast cancer
survival. The workflow shows how the datasets were reduced down at each step and where new datasets were added. The rectangular boxes
represent the gene expression matrices at each stage where the number of pseudogenes, genes, or interactions are reduced
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Starting with the top univariate features from our uni-
variate Cox models, the most precise gene signature
impacting survival is determined by screening out
features with a zero coefficient. A Kaplan-Meier plot
was constructed for each selected feature, including a
summary that revealed the specific p-values. These p-
values enabled us to determine which features were the
most significant biomarkers for determining prognosis.
Specifically, using all of the preselected genes (g ⊆G) and
pseudogenes (p ⊆ P) the following models were fit:
h tjXi;g
  ¼ h0 tð Þ exp Xi;gβg
 
þ βg


1
and
h tjXi;p
  ¼ h0 tð Þ exp Xi;pβp
 
þ βp


1
:
Generating interpretable prognostic models
Using the ctree function from the R partykit package
[33], tree-structured regression models on survival were
constructed taking into account LASSO-generated mo-
lecular signature and clinical variables (such as ethnicity,
race, gender, histological type, pathologic stage, radiation
therapy, race and so on). These tree-structured models
were used to interpret how the given factors influences
one’s survival prognosis in a concise manner.
Integrating gene and pseudogene expression using
pseudogene functional networks
The top genes and pseudogenes that were identified in the
earlier analysis were used as features in the subsequent
pseudogene-gene integrative models. The pseudogene-
gene functional network edge file was obtained from the
BlastDB database (a flavor of the pseudogene-gene family
database) in the PseudoFuN website [21]. The edge be-
tween a gene and a pseudogene indicates that the gene
and pseudogene were contained in the same homology
network and were used to identify the possible interac-
tions between genes and pseudogenes in the model. For
each gene, the corresponding pseudogene(s) were identi-
fied using the BlastDB and the gene-pseudogene inter-
action terms (a) were added to the model. For each
pseudogene, the corresponding gene(s) were identified
using the BlastDB and the pseudogene-gene interaction
terms were added to the model. A LASSO-Cox model was
trained on the genes, pseudogenes, and interaction terms
(a). The non-zero interaction terms were studied using
median expression stratified Kaplan-Meier curves. Specif-
ically, models were trained on all of the retained genes,
pseudogenes, and associated interactions:
h tjXi; g;p;af g
  ¼ h0 tð Þ exp Xi; g;p;af gβ g;p;af g
 
þ β g;p;af g


1
:
The features (genes, pseudogenes, interactions) with
nonzero interactions were retained for further analysis.
For each interaction term with nonzero coefficient, if the
main effects corresponding to that interaction had a zero
coefficient they were retained to improve interpretability
producing the final feature set (l ⊆ {g, p, a}) of genes,
pseudogenes, and interactions and the following model
was fit:
h tjXi;l
  ¼ h0 tð Þ exp Xi;lβl
 
:
External validation of features identified by interpretable
models
Once the final models were fit and the final feature set
was identified, it was important to externally validate the
features that were available outside of the TCGA dataset.
To perform this validation we used a Swedish cohort of
3069 patients (GSE81538). For each gene or pseudogene
in the final Cox model, a Wald test was calculated using
the median feature expression to stratify the patients into
high and low risk groups. The Swedish cohort was strati-
fied into 28 smaller cohorts to explore patient subtyping
in detail by PAM50 status, receptor status (estrogen re-
ceptor, progesterone receptor, and HER2), and age (non-
senior vs. all). These groups help us to further identify
what patient cohorts are identified by what features in the
multiple linear regression Cox model.
Results
miRNAs alone not directly prognostic of breast cancer
survival in our dataset
To assess whether expression of individual miRNAs
bestows prognostic capabilities based on the provided
clinical factors, we used univariate Cox regression
models followed by a multivariate LASSO-Cox model
consisting of both expression and clinical data. None of
the miRNAs were identified as significant in our dataset,
excluding miRNA data from our consideration for fea-
tures in our integrative model.
Gene subsets prognostic of breast Cancer survival
To assess whether expression of individual mRNAs
bestows prognostic capabilities based on the provided
clinical factors, a multivariate LASSO-Cox model,
consisting of both expression and clinical data, was con-
structed (details follow the description in Materials and
Methods). Of the 20,532 gene mRNAs screened by
univariate Cox models, 1007 were significant at the un-
adjusted threshold of p-value < 0.05 and 27 were deemed
statistically significant (BH-FDR < 0.05). To further evalu-
ate the prognostic properties of mRNA expression, a
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multivariate LASSO-Cox model was developed with the
top univariate genes previously found through the univari-
ate Cox models, indicating a molecular signature with 4
key significantly expressed genes: LOC387646, GALP,
STXBP5, and LOC143188. Kaplan-Meier curves were
generated for the 4 most promising genes to further ex-
plore their clinical importance, comparing the specific
gene expression with the median risk-score. High levels of
LOC387646 (Fig. 2a, Wald p-value = 1.0 × 10− 03), GALP
(Fig. 2b, Wald p-value = 3.0 × 10− 06), STXBP5 (Fig. 2c,
Wald p-value = 2.0 × 10− 06), and LOC143188 (Additional
file 1 R compilation output, Wald p-value = 4.0 × 10− 07)
were significantly associated with reduced survival times.
In order to assess the likely outcome of a specific pa-
tient, not only does the molecular expression (mRNA,
miRNA) need to be evaluated, but also clinical variables,
such as ethnicity, race, gender, cancer stage, type, and
radiation therapy status, need to be factored in as well
for more reliable, individualized prognosis. The target
model, based on the data from 769 patients, is summa-
rized and visualized. The ctree function is used to con-
struct a tree that displays the survival curves given the
set of clinical and/or molecular factors. The first tree
generated included only gene expression data, creating
an outline using genes LOC387646, GALP, and STXBP5
(Fig. 2d). Using only these genes, patients could be
stratified into 7 groups based on survival. The following
tree was constructed with both clinical and molecular
data under consideration (Fig. 2e). The tree started with
the assessment of pathologic stage, followed by the ex-
pression level of STXBP5. A patient with the highest
likelihood of survival would fall under Node 8 (Fig. 2e,
Node 8 labeled in bottom of Fig. 2e), and patients could
be stratified into 6 groups based on survival. Aside from
the ability of these genes to predict survival prognosis
we find that STXBP5 protein is detectable at medium
levels in glandular cells from normal breast tissue sam-
ples (Fig. 2f). Since the protein is present in normal
breast tissue, STXBP5 mRNA dysregulation could affect
syntaxin binding protein 5 (STXBP5) protein levels in
BRCA tumor tissue.
Prognostic ability of pseudogenes in breast cancer
Of the 7146 pseudogenes screened using univariate Cox
models, 323 pseudogenes were significant at the
unadjusted threshold of p-value < 0.05 and 14 pseudo-
genes were significant after multiple testing correction at
(BH-FDR < 0.05). Of those, 5 pseudogenes were selected
by a multivariate LASSO-Cox model, CTSLP8,
EEF1GP4, HLA-K, CBX1P3, and RPS10P20. We find
that increased CTSLP8 (Wald p-value = 5.0 × 10− 05), in-
creased EEF1GP4 (Wald p-value = 1.0 × 10− 06), de-
creased HLA-K (Wald p-value = 8.0 × 10− 05), increased
CBX1P3 (Wald p-value = 1.0 × 10− 03), and increased
RPS10P20 (Wald p-value = 2.0 × 10− 03) indicate worse
prognosis in breast cancer (Fig. 3a-c). Furthermore we
find that the patients can be stratified into 4 distinct
groups using a decision tree (all 14 BH-FDR significant
pseudogenes were used as input) on only HLA-K,
RPS10P20, and CTSLP8 (Fig. 3d). When clinical vari-
ables are added to the model, the patients can be further
stratified into 6 groups (Fig. 3e). Individually, HLA-K
has the most prognostic utility in breast cancer since
median separation splits the patients (50.1 to 49.9%).
Using the 323 unadjusted significant pseudogenes we are
able to combine with the 1,007 unadjusted significant
genes to produce a combined model of BRCA prognosis.
Prognostic ability of pseudogene-gene interactions from
PseudoFuN
The interactions between pseudogenes and genes are
known to have an influence in multiple types of cancer
[16–18, 35]. We use the unadjusted gene set and un-
adjusted pseudogene set as a starting point to determine
possible pseudogene-gene interactions. From the Pseu-
doFuN database, we found 77 candidate interactions that
were added to the model. From the genes, pseudogenes,
and interactions features we found that 40 total features
had non-zero coefficients in our LASSO-Cox model and
one corresponded to pseudogene-gene interactions. We
fit the following model to our data using Cox regression
on the retained gene, pseudogene, interaction, and inter-
action main effects resulting in 42 total features.
h tjXi;l
  ¼ h0 tð Þ exp

1:43SLITRK3þ 14:21GALP
þ2:79OR4C13þ 3:23VN1R4þ 4:84LCE3C
þ−0:11STXBP5þ 0:01IYD þ 0:51ARID1B
þ0:78SMR3Aþ −0:08DIP2Bþ 1:34
LOC100101266þ −0:12C19orf 66þ −1:02
PARP12þ 0:21EXOC1þ −0:54CELþ 0:63
SLC9A1þ −0:09CCDC28Bþ 0:59PCMT1
þ1:88C10orf 131þ 0:78HARS2þ 1:69CELP
þ0:82C7orf 53þ 1:33OR52E6þ 0:18HBS1L
þ11:26MEMO1P3þ 0:34HLA K þ 1:33
GVINP2þ 4:78RPS10P20þ 5:93HSPA8P1
þ0:47GAPDHP45þ 3:04ANKRD30BP2
þ10:48RPS20P25þ 10:79KRT18P62þ 16:82
OR7E10P þ 0:26SCML2P1þ 7:42RPL5P28
þ2:56RPS27P12þ 0:52PRR13P5þ −2:21
IGKV2D 23þ −0:11GPS2þ −6:96GPS2P1
þ1:20GPS2 : GPS2P1
Increased GPS2-GPS2P1 (Wald p-value = 2.0 × 10− 03)
expression interaction indicates better prognosis (Fig.
4a). These observations are of interest considering
neither the gene nor pseudogene alone are significant
predictors of survival prognosis representing a cross-
over (i.e., disordinal) interaction. Furthermore, we found
that GPS2 protein is detectable at medium levels in both
glandular cells and myoepithelial cells from normal
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breast tissue in the Human Protein Atlas [36] (Fig. 4c).
GPS2 and GPS2P1 are uncorrelated in normal tissue but
are correlated in primary tumor samples [21] (Fig. 4d, e)
achieving a significantly higher correlation in tumor tis-
sue (Fisher’s r to z transformation p-value < 0.0001).
This relationship can indicate a regulatory change in
breast cancer tissue. The TCGA miRNA data also shows
that miR-3923 is significantly negatively correlated with
GPS2 and predicted to target GPS2 by miRanda [37],
PicTar [38], and TargetScan [39]. Upon further investi-
gation, GPS2-GPS2P1 have high sequence homology in
the top 1% of all comparisons in the PseudoFuN
Fig. 2 Prognostic gene models in BRCA. a Kaplan-Meier survival plot for LOC387646. b Kaplan-Meier survival plot for GALP. c Kaplan-Meier
survival plot for STXBP5. D) Decision tree based on only gene expression data excluding clinical variables. e Decision tree based on gene
expression and clinical variables. f Histology staining from the Human Protein Atlas [34] for STXBP5 in normal tissue (includes: gender, age, tissue
type, and antibody used in bold on the histology slide). For example, F35 means a 35-year-old female, and HPA049727 is the antibody. The tissue
staining is used to show that the specific protein product is present in normal tissue. Thus regulating that gene (STXBP5) at the mRNA level
might affect the phenotype because the protein product is present and can be a regulation target
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database. These observations are indicative of a ceRNA
network. Considering that GPS2 siRNA knock-down
causes increased proliferation of MCF-7 BRCA cell line
[40], the GPS2-GPS2P1 interaction is an exciting pro-
spect in BRCA regulation.
Since the interpretation of cross-over interactions is
more complicated we further evaluated the relationships
between the independent and dependent variables in the
cross-over interaction, GPS2-GPS2P1. GPS2P1 was posi-
tively correlated with GPS2 at high levels of GPS2P1
(Fig. 5b) and negatively correlated with GPS2 at low
levels of GPS2P1 (Fig. 5c). These correlations were sig-
nificantly different (Fisher’s r to z transformation p-value
< 0.0001). We found for both interactions that
pseudogene high expression and pseudogene low expres-
sion groups had a different association between the gene
and survival using the subset of patients with events.
Only the patients with events could be used so that the
survival time in months was a valid dependent variable.
The starkest relationship is that of GPS2 and GPS2P1
where GPS2 in the high GPS2P1 group was positively
correlated with survival time while GPS2 in the low
GPS2P1 group was negatively associated with survival
time (Fig. 5d). These results could imply even more
complicated interactions between genes and pseudo-
genes than previously understood. Ideally, more samples
are needed to study the effect of pseudogene expression
on gene-survival associations considering there were
Fig. 3 Prognostic pseudogene models in BRCA. a Kaplan-Meier survival plot for PGK1. b Kaplan-Meier survival plot for PTCHD4. c Decision tree
based on only pseudogene expression data without clinical variables. d Decision tree based on pseudogene expression and clinical variables
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only 114 events (i.e., uncensored patient with time to
survival) which drastically reduced our sample size in
the gene-survival time comparisons.
External validation of genes identified by interpretable
models
In total 24 of the 42 Cox model features (see Prognostic
Ability of Pseudogene-Gene Interactions from Pseudo-
FuN) were also found in the Swedish cohort and the ma-
jority (16/18) of the missing features were pseudogenes.
In fact, ANKRD30BP2 was the only pseudogene found
in the Swedish cohort expression data. This is not
surprising considering pseudogene expression is under-
studied, i.e., most datasets do not have quantified
pseudogene expression and dreamBase has only calcu-
lated the pseudogene expression in TCGA data. Also,
the pseudogene reads are most likely being assigned to a
close homology sister genes. Pseudogene ANKRD30BP2
was found significantly associated with survival in the
non-senior PAM50-normal patients (Wald p-value =
3.73 × 10− 2) and non-senior ER+HER2+ patients (Wald
p-value = 3.73 × 10− 2) from the Swedish cohort. Of the
25 genes in the Cox model, 23 were found in the Swed-
ish cohort and 16 of those genes were significant (Wald
p-value < 5.00 × 10− 2) in at least one of the Swedish
groups of patients. GPS2 was found to be associated
with survival in non-senior patients (Wald p-value =
3.58 × 10− 2). These analyses also allow us to identify
Fig. 4 Pseudogene-gene interactions as survival prognosis features in BRCA. a Kaplan-Meier survival plot for GPS2-GPS2P1 interaction. b Histology
staining from the Human Protein Atlas for GPS2 in normal tissue (includes: gender, age, tissue type, and antibody used in bold on the histology
slide). The tissue staining is used to show that some protein product is present in normal tissue which could be affected by pseudogene
regulation. c GPS2-GPS2P1 coexpression in normal and d tumor tissue in BRCA samples
Smerekanych et al. BMC Medical Genomics 2020, 13(Suppl 5):51 Page 9 of 13
features that help stratify difficult to treat breast cancer
subtypes, i.e., GALP, IYD, and PARP12 were all signifi-
cantly associated with survival in non-senior triple-
negative breast cancer patients. Additionally, all of the
Wald p-values for each model feature in the Swedish co-
hort groups are contained in Additional file 2: Table S1.
Discussion
Insights
Many factors play a role on an individual’s prognosis, as
demonstrated by the range of outcomes from our gener-
ated prognostic decision trees. One cannot assume an
accurate prognosis simply based on molecular expres-
sion or clinical information - they should be considered
as a unit. Not only do multiple factors need to be in-
cluded for but likely molecular interactions must also be
accounted for. Through LASSO-Cox regression and
ctree visualization, it became apparent that high STXBP5
expression is a reliable indicator of a poor prognosis.
STXBP5 encodes syntaxin binding protein 5 which can
be readily detected in breast tissue (Fig. 2f). Perhaps
what is most interesting is the mechanism that STXBP5
affects cancerous tissue. STXBP5-AS1 is a long non-cod-
ing RNA from the STXBP5 gene which is prognostic for
breast cancer survival and may be regulated by miR-190
through ceRNA network interactions [41, 42]. Our re-
sults further support these previous findings and the
idea of non-coding regulation of gene expression in
cancer. It is important to not only view expression
biomarkers from a gene level, and pseudogenes should
also be considered.
Decreased HLA-K pseudogene expression was prog-
nostic of poor patient survival. This finding is supported
in the literature where multiple human leukocyte anti-
gen (HLA) genes have been implicated in immune
response to breast cancer [43]. Since the HLA genes en-
code major histocompatibility complex class I (MHC1)
proteins, it is perhaps not surprising that a related
Fig. 5 GPS2-GPS2P1 interaction terms and relationship with survival. All plots with survival included use the subset of patients with an event. a-c
GPS2 and GPS2P1 associations including b GPS2 correlation with GPS2P1 for GPS2P1 high group (> 0.1, blue line in D, above red line in a and c
GPS2 correlation with GPS2P1 for GPS2P1 low group (≤0.1, red line in D, below red line in a. d GPS2 association with survival for GPS2P1 high
and low groups. Line color indicates the fit to the corresponding colored points and black color indicates all points. Note that only samples with
events (i.e., survival times) could be used in d
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pseudogene is prognostic. HLA pseudogenes have long
been known to exist [44, 45] but the regulation of HLA
genes by these pseudogenes has been understudied.
Considering HLA genes are directly related to patient
response to immunotherapy in lung cancer [46] and
disease free survival in breast cancer [47], HLA-K should
be further investigated.
Aside from identifying multiple individual genes and
pseudogenes that are prognostic of patient survival, we
leveraged prior knowledge of possible pseudogene-gene
interactions from PseudoFuN [21] to identify prognostic
interactions between genes and pseudogenes. In the case
of GPS2-GPS2P1 there is clear evidence that the protein
is expressed in normal breast tissue, that GPS2 and
GPS2P1 are positively correlated in tumor samples (i.e.,
positive correlation is indicative of ceRNA interaction),
there is evidence of miRNA targeting GPS2, and there
are external experimental findings showing GPS2
miRNA regulation causes breast cancer cell proliferation
by reducing GPS2 protein levels. Furthermore, we see
interesting cross-over interactions in GPS2-GPS2P1
where the relationship between GPS2 and GPS2P1
changes as GPS2P1 expression increases. We also see
changes in the relationship between GPS2 and survival
time based on the expression of GPS2P1. Additionally
this general wrokflow can be used in multiple cancer
types since the pseudogene expression data is available
for most TCGA cancer types.
With these considerations in mind, it should be
possible to find additional genes, pseudogenes, and
interactions in other cancers. Pseudogenes and
pseudogene-gene interactions that are consistent across
multiple cancers may be of interest as gene regulatory
cancer drivers. Our integrative methodology, combining
genes, pseudogenes, miRNAs, clinical variables, and a
priori interaction information can improve the feature
sets we use to model the complex systems in cancer.
Limitations
Due to the dataset availability, we did not have an ex-
tremely large patient pool to work from. As more
samples become available, our models should con-
tinue to be strengthened. With a larger sample size,
we should find significance with miRNA data, enhan-
cing our molecular model. Additionally, a larger sam-
ple size would increase the variety in patient clinical
factors as well as the number of adverse events. Fur-
thermore, pseudogene functional analysis and expres-
sion analysis is understudied resulting in a lack of
these valuable data points for most available datasets.
As a result, it is of the upmost importance to per-
form analyses like these shown so that the pseudo-
gene knowledgebase can be enlarged.
Conclusion
Given the highly unique characteristics cancer takes on
in each impacted individual, the possibility of an effect-
ive universal cure is unlikely. Treatments have shifted to
a more targeted approach to the molecular factors of
specific subtypes. Furthermore, we are discovering novel
regulatory relationships between different types of RNAs
that can be leveraged in predictive models. Through
statistically identifying key genes, pseudogenes, interac-
tions and clinical factors impacting breast cancer sur-
vival to a more precise degree, treatments can become
more individualized. Our study focuses on the use of a
priori pseudogene-gene functional interactions to guide
the features we use in predictive models. It is our con-
viction that by overlaying these regulatory relationships
we can use the resulting interaction terms to improve
the predictive accuracy of most any individual model
type. We plan to use more regulatory data types (pro-
tein, expression and histology images) in further analysis
to identify key interactions as features and to test alter-
native models such as random survival forests [48] and
Cox-nnet neural networks [49].
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12920-020-0687-0.
Additional file 1. This file contains the R markdown output for the
analysis. The plots and code in this file were directly used to generate
the statistics and figures in the manuscript.
Additional file 2. This file contains the p-values for univariate cox pro-
portional hazard models on each of the genes from our model in the
Swedish cohort. The test was performed on multiple subsets of patients
including age and breast cancer subtype using median expression as the
cutoff.
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